# Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

> **NCT02229214** · PHASE4 · COMPLETED · sponsor: **VIVUS LLC** · enrollment: 51 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Qsymia
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02229214
- **Lead sponsor:** VIVUS LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229214, "Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02229214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*